1. US cost-effectiveness of polatuzumab vedotin, bendamustine and rituximab in diffuse large B-cell lymphoma.
- Author
-
Betts KA, Thuresson PO, Felizzi F, Du EX, Dieye I, Li J, Schulz M, and Masaquel AS
- Subjects
- Adolescent, Adult, Aged, Antibodies, Monoclonal therapeutic use, Antineoplastic Agents therapeutic use, Cost-Benefit Analysis, Humans, Immunoconjugates therapeutic use, Lymphoma, Large B-Cell, Diffuse mortality, Middle Aged, Survival Rate, Treatment Outcome, Antibodies, Monoclonal economics, Antineoplastic Agents economics, Bendamustine Hydrochloride economics, Immunoconjugates economics, Lymphoma, Large B-Cell, Diffuse drug therapy, Rituximab economics
- Abstract
Aim: To evaluate the cost-effectiveness of polatuzumab vedotin (pola) + bendamustine + rituximab (BR) in relapsed/refractory diffuse large B-cell lymphoma based on the GO29365 trial from a US payer's perspective. Materials & methods: A partitioned survival model used progression-free survival and overall survival data from the GO29365 trial. The base case analysis assumed overall survival was informed by progression-free survival; a mixture cure model estimated proportion of long-term survivors. Results: In the base case, pola + BR was cost-effective versus BR at US$35,864 per quality-adjusted life year gained. Probabilistic and one-way sensitivity analyses showed that the findings were robust. Conclusion: Pola + BR is cost-effective versus BR for the treatment of transplant-ineligible relapsed/refractory diffuse large B-cell lymphoma in the US. more...
- Published
- 2020
- Full Text
- View/download PDF